Abstract:Introduction: Type II diabetes mellitus (T2DM) is a metabolic disorder that poses a serious health concern worldwide due to its rising prevalence. Hypertension (HT) is a frequent comorbidity of T2DM, with the co-occurrence of both conditions increasing the risk of diabetes-associated complications. Inflammation and oxidative stress (OS) have been identified as leading factors in the development and progression of both T2DM and HT. However, OS and inflammation processes associated with these two comorbidities are not fully understood. This study aimed to explore changes in the levels of plasma and urinary inflammatory and OS biomarkers, along with mitochondrial OS biomarkers connected to mitochondrial dysfunction (MitD). These markers may provide a more comprehensive perspective associated with disease progression from no diabetes, and prediabetes, to T2DM coexisting with HT in a cohort of patients attending a diabetes health clinic in Australia. Methods: Three-hundred and eighty-four participants were divided into four groups according to disease status: 210 healthy controls, 55 prediabetic patients, 32 T2DM, and 87 patients with T2DM and HT (T2DM+HT). Kruskal-Wallis and χ2 tests were conducted between the four groups to detect significant differences for numerical and categorical variables, respectively. Results and discussion: For the transition from prediabetes to T2DM, interleukin-10 (IL-10), C-reactive protein (CRP), 8-hydroxy-2'-deoxyguanosine (8-OHdG), humanin (HN), and p66Shc were the most discriminatory biomarkers, generally displaying elevated levels of inflammation and OS in T2DM, in addition to disrupted mitochondrial function as revealed by p66Shc and HN. Disease progression from T2DM to T2DM+HT indicated lower levels of inflammation and OS as revealed through IL-10, interleukin-6 (IL-6), interleukin-1β (IL-1β), 8-OHdG and oxidized glutathione (GSSG) levels, most likely due to antihypertensive medication use in the T2DM +HT patient group. The results also indicated better mitochondrial function in this group as shown through higher HN and lower p66Shc levels, which can also be attributed to medication use. However, monocyte chemoattractant protein-1 (MCP-1) levels appeared to be independent of medication, providing an effective biomarker even in the presence of medication use. The results of this study suggest that a more comprehensive review of inflammation and OS biomarkers is more effective in discriminating between the stages of T2DM progression in the presence or absence of HT. Our results further indicate the usefulness of medication use, especially with respect to the known involvement of inflammation and OS in disease progression, highlighting specific biomarkers during disease progression and therefore allowing a more targeted individualized treatment plan.

Relationship between serum markers of oxidative stress and early stage diabetic nephropathy as well as metabolic syndrome

Relationship between serum lutein and oxidative stress in patients with type 2 diabetes mellitus

Relationship between metabolic syndrome and early-stage diabetic nephropathy in type 2 diabetes mellitus

Biomarkers of Oxidative Stress in Diabetes Mellitus with Diabetic Nephropathy Complications

Investigation of oxidative stress markers and antioxidant enzymes activity in newly diagnosed type 2 diabetes patients and healthy subjects, association with IL-6 level

Decreased total antioxidant levels and increased oxidative stress in South African type 2 diabetes mellitus patients

Evaluation of Oxidative Stress level and some Antioxidant enzymes activity parameters in patients with type two diabetes mellitus

Biomarkers of Oxidative Stress and Their Clinical Relevance in Type 2 Diabetes Mellitus Patients: A Systematic Review

Augmented Nadph Oxidase Activity and P22phox Expression in Monocytes Underlie Oxidative Stress of Patients with Type 2 Diabetes Mellitus

Study on the relationship between DNA oxidative damage and macrovascular complications in patients with type 2 diabetes

Clinical analysis of oxidative stress damage and inflammatory markers in patients with impaired glucose regulation

Clinical Significance of Determination of Serum Cystatin C,lipoprotein (α) and High Sensitivity C-reactive Protein in Type 2 Diabetic Patients with Early Renal Impairment.

Oxidative stress indices and endothelial dysfunction in type 2 diabetes: risks and focus on diet therapy

The clinical research about the relationship between serum levels of 8-hydroxy-deoxyguanosine (8-OHdG) of type 2 diabetes patients and its macrovascular complications

Clinical markers and some trace elements in patients with type-2 diabetic nephropathy : Impact of insulin resistance.

Relationship between serum levels of 8-OHdG and macrovascular complications in type-2 diabetes patients

Serum and Urinary Metabolomic Analysis in Patients with Diabetic Nephropathy

Oxidative stress markers in diabetes

Inflammation, oxidative stress and mitochondrial dysfunction in the progression of type II diabetes mellitus with coexisting hypertension

Advances in oxidative stress in pathogenesis of diabetic kidney disease and efficacy of TCM intervention